AMGN · Amgen Inc.
$439.26
-1.79% last session
End-of-day data · close of 2026-10-23
Market cap
$237B
Enterprise value
$281B
Trailing P/E
27.3
Forward P/E
17.9
Dividend yield
2.0%
Beta
0.41
Avg volume
3M
Employees
32K
Daily Change %
-1.79%
5 Days Change
3.42%
10 Days Change
8.34%
30 Days Change
10.14%
60 Days Change
0.78%
Month to Day Change
9.82%
Year to Day Change
39.45%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AMGN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-23
Latest call per bank · past 12 months
Barclays
Equal-Weight$400
-8.9% vs priceWells Fargo
Equal-Weight$430
-2.1% vs priceUBS
Buy$470
+7.0% vs priceRBC Capital
Outperform$430
-2.1% vs priceMorgan Stanley
Equal-Weight$359
-18.3% vs priceHSBC
Hold$425
-3.2% vs priceCitigroup
Neutral$405
-7.8% vs priceBank of America
Underperform$317
-27.8% vs priceGoldman Sachs
Buy$450
+2.4% vs priceJefferies
Hold$350
-20.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-23 | Oppenheimer | Maintains | Outperform | $450 → $480 |
| 2026-10-21 | Barclays | Maintains | Equal-Weight | $380 → $400 |
| 2026-10-13 | Guggenheim | Maintains | Neutral | $388 → $378 |
| 2026-10-12 | BMO Capital | Maintains | Market Perform | $450 → $415 |
| 2026-10-12 | Wells Fargo | Maintains | Equal-Weight | $435 → $430 |
| 2026-10-09 | UBS | Maintains | Buy | $430 → $470 |
| 2026-10-08 | RBC Capital | Maintains | Outperform | $400 → $430 |
| 2026-10-08 | Cantor Fitzgerald | Maintains | Neutral | $400 → $440 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 61 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 5.3% above the 50-day MA ($417.01).
- bullish: Price vs 200-day MA: Trading 19.2% above the 200-day MA ($368.54).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+2.75) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($447.28).
AMGN Price Chart
Loading chart for AMGN…
Fundamentals
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.